Nucleotide Nutrition Corporate Identity & Advertising

•

Nucleotide Nutrition
Stage one : Corporate identity & advertising

Nucleotide Nutrition Limited (an existing client formally named Pro Bio Healthcare) approached dbcs to handle their brand repositioning and name change.

Offering a unique portfolio of revolutionary nucleotide-based healthcare products, effective for a wide range of modern lifestyles and dietary deficiencies (see below all interested in the science*), Nucleotide Nutrition needed their new identity to convey their exclusivity in, and passion for, their niche market place. They needed an individual and instantly recognisable visual solution that hinted at the scientific "building blocks of DNA" theme behind all their products while remaining friendly, commercially "acceptable" and, most importantly, "non-threatening". The emphasis on the "natural" aspect of their product's unique ingredient would be maintained by the retention of the Pro Bio tag-line "the natural approach" along with the existing green corporate colour palette – two decisions also made in an effort not to alienate existing customers.

The remaining stages of the Nucleotide Nutrition brand repositioning process: individual product development (inc. advertising, packaging, brochures & POS) and corporate/product web site design/re-design will appear here as separate projects once each stage is completed.

*Nucleotide Nutrition offer a range of food supplements derived from 100% natural products, each one incorporating the ground-breaking and exclusive Nutri-tide™ nucleotide nutritional formula. Products that are individually targeted to provide nutritional solutions effective for a wide range of modern lifestyles and dietary deficiencies – from people who suffer from bowel problems or with the symptoms of IBS, to people who simply lead hectic lifestyles and need a regular boost to their immune system. With many more targeted products in the pipe-line (inc. a sports solution that may help improve recovery times) Nucleotide Nutrition remain committed to the development of new nucleotide-based solutions.